The number of 3,4-methylenedioxymethamphetamine (ecstasy or MDMA) animal research articles is rapidly increasing and yet studies which place emphasis on the clinical signi.cance are limited due to a lack of reliable human data. MDMA produces an acute, rapid release of brain serotonin and dopamine in experimental animals and in the rat this is associated with increased locomotor activity and the serotonin behavioural syndrome in rats. MDMA causes dose-dependent hyperthermia, which is potentially fatal, in humans, primates and rodents. Subsequent serotonergic neurotoxicity has been demonstrated by biochemical and histological studies and is reported to last for months in rats and years in non-human primates. Relating human data to .ndings in animals is complicated by reports that MDMA exposure in mice produces selective long-term dopaminergic impairment with no effect on serotonin. This review compares data obtained from animal and human studies and examines the acute physiological, behavioural and biochemical effects of MDMA as well as the long-term behavioural effects together with serotonergic and dopaminergic impairments. Consideration is also given to the role of neurotoxic metabolites and the in.uence of age, sex and user groups on the long-term actions of MDMA.
Aguirre N, Ballaz S, Lasheras B, Del Rio J (1998) MDMA (‘Ecstasy’) enhances 5-HT1A receptor density and 8-OH-DPAT-induced hypothermia: blockade by drugs preventing 5-hydroxytryptamine depletion. Eur J Pharmacol346: 181–188
2.
Bai F, Lau S S, Monks T J (1999) Glutathione and N-acetylcysteine conjugates of alpha-methyldopamine produce serotonergic neurotoxicity: possible role in methylenedioxyamphetamine-mediated neurotoxicity. Chem Res Toxicol12: 1150–1157
3.
Bai F, Jones D C, Lau S S, Monks T J (2001) Serotonergic neurotoxicity of 3,4-(+/-)-methylenedioxyamphetamine and 3,4-(+/-)-methylendioxymethamphetamine (ecstasy) is potentiated by inhibition of gamma-glutamyl transpeptidase. Chem Res Toxicol14: 863–870
4.
Bankson M G, Cunningham K A (2002) Pharmacological studies of the acute effects of (+)-3,4-methylenedioxymethamphetamine on locomotor activity: Role of 5-HT1B/1D and 5-HT2C receptors. Neuropsychopharmacology26: 140–152
5.
Battaglia G, Yeh S Y, De Souza E B (1988) MDMA-induced neurotoxicity: parameters of degeneration and recovery of brain serotonin neurons. Pharmacol Biochem Behav29: 269–274
6.
Battaglia G, Yeh S Y, O'Hearn E, Molliver M E, Kuhar M J, De Souza E B (1987) 3,4-Methylenedioxymethamphetamine and 3,4-methylenedioxyamphetamine destroy serotonin terminals in rat brain: quantification of neurodegeneration by measurement of [3H]paroxetine-labeled serotonin uptake sites. J Pharmacol Exp Ther242: 911–916
7.
Bhattachary S, Powell J H (2001) Recreational use of 3,4-methylenedioxymethamphetamine (MDMA) or ‘ecstasy’: evidence for cognitive impairment. Psychol Med31: 647–658
8.
Bodenham A R, Mallick A (1996) New dimensions in toxicology: hyperthermic syndrome following amphetamine derivatives. Intensive Care Med22: 622–624
9.
Bolla K I, McCann U D, Ricaurte G A (1998) Memory impairment in abstinent MDMA (‘Ecstasy’) users. Neurology51: 1532–1537
10.
Bowyer J F, Harris A J, Delongchamp R R, Jakab, R L, Miller D B, Little A R, O'Callaghan J P (2004) Selective changes in gene expression in cortical regions sensitive to amphetamine during the neurodegenerative process. Neurotoxicology25: 555–572
11.
Broening H W, Bacon L, Slikker W Jr (1994) Age modulates the longterm but not the acute effects of the serotonergic neurotoxicant 3,4-methylenedioxymethamphetamine. J Pharmacol Exp Ther271: 285–293
12.
Broening H W, Bowyer J F, Slikker W Jr (1995) Age-dependent sensitivity of rats to the long-term effects of the serotonergic neurotoxicant (+/-)-3,4-methylenedioxymethamphetamine (MDMA) correlates with the magnitude of the MDMA-induced thermal response. J Pharmacol Exp Ther275: 325–333
13.
Broening H W, Morford L L, Inman-Wood S L, Fukumura M, Vorhees C V (2001) 3,4-methylenedioxymethamphetamine (ecstasy)-induced learning and memory impairments depend on the age of exposure during early development. J Neurosci21: 3228–3235
14.
Bubar M J, Pack K M, Frankel P S, Cunningham K A (2004) Effects of dopamine D1- or D2-like receptor antagonists on the hypermotive and discriminative stimulus effects of (+)-MDMA. Psychopharmacology173: 326–336
15.
Buchert R, Thomasius R, Wilke F, Petersen K, Nebeling B, Obrocki J, Schulze O, Schmidt U, Clausen M (2004) A voxel-based PET investigation of the long-term effects of ‘Ecstasy’ consumption on brain serotonin transporters. Am J Psychiatry161: 1181–1189
16.
Buchert R, Thomasius R, Nebeling B, Petersen K, Obrocki J, Jenicke L, Wilke F, Wartberg L, Zapletalova P, Clausen M (2003) Long-term effects of ‘ecstasy’ use on serotonin transporters of the brain investigated by PET. J Nucl Med44: 375–384
17.
Bull E J, Hutson P H, Fone K C (2003) Reduced social interaction following 3,4-methylenedioxymethamphetamine is not associated with enhanced 5-HT 2C receptor responsivity. Neuropharmacology44: 439–448
18.
Bull E J, Hutson P H, Fone K C (2004) Decreased social behaviour following 3,4-methylenedioxymethamphetamine (MDMA) is accompanied by changes in 5-HT2A receptor responsivity. Neuropharmacology46: 202–210
19.
Cadet J L, Ladenheim B, Baum I, Carlson E, Epstein C (1994) CuZnsuperoxide dismutase (CuZnSOD) transgenic mice show resistance to the lethal effects of methylenedioxyamphetamine (MDA) and of methylenedioxymethamphetamine (MDMA). Brain Res655: 259–262
20.
Callaway C W, Wing L L, Geyer M A (1990) Serotonin release contributes to the locomotor stimulant effects of 3,4-methylenedioxymethamphetamine in rats. J Pharmacol Exp Ther254: 456–464
21.
Callaway C W, Rempel N, Peng R Y, Geyer M A (1992) Serotonin 5-HT1-like receptors mediate hyperactivity in rats induced by 3,4-methylenedioxymethamphetamine. Neuropsychopharmacology7 (2): 113–127
22.
Camarero J, Sanchez V, O'shea E, Green A R, Colado M I (2002) Studies, using in vivo microdialysis, on the effect of the dopamine uptake inhibitor GBR 12909 on 3,4-methylenedioxymethamphetamine (‘ecstasy’)-induced dopamine release and free radical formation in the mouse striatum. J Neurochem81: 961–972
23.
Capela J P, Meisel A, Abreu A R, Branco P S, Ferreira L M, Lobo A M, Remiao F, Bastos M L, Carvalho F (2005) Neurotoxicity of Ecstasy metabolites in rat cortical neurons. Influence of hyperthermia. J Pharmacol Exp Ther23: online
24.
Carvalho M, Carvalho F, Remiao F, de Lourdes Pereira M, Pires-das-Neves R, de Lourdes Bastos M (2002) Effect of 3,4-methylenedioxymethamphetamine (‘ecstasy’) on body temperature and liver antioxidant status in mice: influence of ambient temperature. Arch Toxicol76: 166–172
25.
Carvalho M, Milhazes N, Remiao F, Borges F, Fernandes E, Amado F, Monks T J, Carvalho F, Bastos M L (2004) Hepatotoxicity of 3,4-methylenedioxyamphetamine and alpha-methyldopamine in isolated rat hepatocytes: formation of glutathione conjugates. Arch Toxicol78: 16–24
26.
Chang L, Ernst T, Grob C S, Poland R E (1999) Cerebral (1)H MRS alterations in recreational 3,4-methylenedioxymethamphetamine (MDMA, ‘ecstasy’) users. J Magn Reson Imaging10: 521–526
27.
Che S, Johnson M, Hanson G R, Gibb J W (1995) Body temperature effect on methylenedioxymethamphetamine-induced acute decrease in tryptophan hydroxylase activity. Eur J Pharmacol293: 447–453
28.
Cho A K, Hiramatsu M, Distefano, E W, Chang, A S, Jenden, D J (1990) Stereochemical differences in the metabolism of 3,4-methylenedioxymethamphethamine in vitroand in vivo: a pharmacokinetic analysis. Drug Metab Disposition18: 686–691
29.
Chu T, Kumagai Y, DiStefano E W, Cho A K (1996) Disposition of methylenedioxymethamphetamine and three metabolites in the brains of different rat strains and their possible roles in acute serotonin depletion. Biochem Pharmacol51: 789–796
30.
Chung K K, Dawson V L, Dawson T M (2003) New insights into Parkinson's disease. J Neurol250(Suppl. 3): III15–III24
31.
Clemens K J, Cornish J L, Li K M, Hunt G E, McGregor I S (2005) MDMA (‘ecstasy’) and methamphetamine combined: Order of administration influences hyperthermic and long-term adverse effects in female rats. Neuropharmacology49: 195–207
32.
Clemens K J, Van Nieuwenhuyzen P S, Li K M, Cornish J L, Hunt G E, McGregor I S (2004) MDMA (‘ecstasy’), methamphetamine and their combination: long-term changes in social interaction and neurochemistry in the rat. Psychopharmacology (Berl)173: 318–325
33.
Cohen M A, Skelton M R, Schaefer T L, Gudelsky G A, Vorhees C V, Williams M T (2005) Learning and memory after neonatal exposure to 3,4-methylenedioxymethamphetamine (ecstasy) in rats: interaction with exposure in adulthood. Synapse57: 148–159
34.
Colado M I, Murray T K, Green A R (1993) 5-HT loss in rat brain following 3,4-methylenedioxymethamphetamine (MDMA), pchloroamphetamine and fenfluramine administration and effects of chlormethiazole and dizocilpine. Br J Pharmacol108: 583–589
35.
Colado M I, O'shea E, Green A R (2004) Acute and long-term effects of MDMA on cerebral dopamine biochemistry and function. Psychopharmacology (Berl)173: 249–263
36.
Colado M I, Williams J L, Green A R (1995) The hyperthermic and neurotoxic effects of ‘Ecstasy’ (MDMA) and 3,4 methylenedioxyamphetamine (MDA) in the Dark Agouti (DA) rat, a model of the CYP2D6 poor metabolizer phenotype. Br J Pharmacol115: 1281–1289
37.
Colado M I, O'shea E, Esteban B, Granados R, Green A R (1999a) In vivo evidence against clomethiazole being neuroprotective against MDMA (‘ecstasy’)-induced degeneration of rat brain 5-HT nerve terminals by a free radical scavenging mechanism. Neuropharmacology38: 307–314
38.
Colado M I, O'shea E, Granados R, Murray T K, Green A R (1997) In vivo evidence for free radical involvement in the degeneration of rat brain 5-HT following administration of MDMA (‘ecstasy’) and pchloroamphetamine but not the degeneration following fenfluramine. Br J Pharmacol121: 889–900
39.
Colado M I, O'shea E, Granados R, Esteban B, Martin A B, Green A R (1999b) Studies on the role of dopamine in the degeneration of 5-HT nerve endings in the brain of Dark Agouti rats following 3,4-methylenedioxymethamphetamine (MDMA or ‘ecstasy’) administration. Br J Pharmacol126: 911–924
40.
Colado M I, Camarero J, Mechan A O, Sanchez V, Esteban B, Elliott J M, Green A R (2001) A study of the mechanisms involved in the neurotoxic action of 3,4-methylenedioxymethamphetamine (MDMA, ‘ecstasy’) on dopamine neurones in mouse brain. Br J Pharmacol134: 1711–1723
41.
Cole J C, Sumnall H R, Smith G W, Rostami-Hodjegan A (2005) Preliminary evidence of the cardiovascular effects of polysubstance misuse in nightclubs. J Psychopharmacol19: 67–70
42.
Commins D L, Vosmer G, Virus R M, Woolverton W L, Schuster C R, Seiden L S (1987) Biochemical and histological evidence that methylenedioxymethylamphetamine (MDMA) is toxic to neurons in the rat brain. J Pharmacol Exp Ther241: 338–345
43.
Creighton F J, Black D L, Hyde C E (1991) ‘Ecstasy’ psychosis and flashbacks. Br J Psychiatry159: 713–715
44.
Dafters R I (1994) Effect of ambient temperature on hyperthermia and hyperkinesis induced by 3,4-methylenedioxymethamphetamine (MDMA or ‘ecstasy’) in rats. Psychopharmacology (Berl)114: 505–508
45.
Dafters R I, Lynch E (1998) Persistent loss of thermoregulation in the rat induced by 3,4-methylenedioxymethamphetamine (MDMA or ‘Ecstasy’) but not by fenfluramine. Psychopharmacology138: 207–212
46.
Damier P, Hirsch E C, Agid Y, Graybiel A M (1999) The substantia nigra of the human brain. II. Patterns of loss of dopamine-containing neurons in Parkinson's disease. Brain122: 1437–1448
47.
Daniela E, Brennan K, Gittings D, Hely L, Schenk S (2004) Effects of SCH 23390 on (+/-)-3,4-methylenedioxymethamphetamine hyperactivity and self-administration in rats. Pharmacol Biochem Behav77: 745–750
48.
de la Torre R, Farre M (2004) Neurotoxicity of MDMA (ecstasy): the limitations of scaling from animals to humans. Trends Pharmacol Sci25: 505–508
49.
de la Torre R, Farre M, Monks T J, Jones D (2005) Response to Sprague and Nichols: Contribution of metabolic activation to MDMA neurotoxicity. Trends Pharmacol Sci26: 60–61
50.
de la Torre R, Farre M, Ortuno J, Mas M, Brenneisen R, Roset P N, Segura J, Cami J (2000a) Non-linear pharmacokinetics of MDMA (‘ecstasy’) in humans. Br J Clin Pharmacol49: 104–109
51.
de la Torre R, Farre M, Roset P N, Hernandez Lopez C, Mas M, Ortuno J, Menoyo E, Pizarro N, Segura J, Cami J (2000b) Pharmacology of MDMA in humans. Ann N Y Acad Sci914: 225–237
52.
De Souza I, Kelly J P, Harkin A J, Leonard B E (1997) An appraisal of the pharmacological and toxicological effects of a single oral administration of 3,4-methylenedioxymethamphetamine (MDMA) in the rat. Pharmacol Toxicol80: 207–210
53.
de Win M M, de Jeu R A, de Bruin K, Habraken J B, Reneman L, Booij J, den Heeten G J (2004) Validity of in vivo [123I]beta-CIT SPECT in detecting MDMA-induced neurotoxicity in rats. Eur Neuropsychopharmacol14: 185–189
54.
Doblin R (2002) A clinical plan for MDMA (Ecstasy) in the treatment of posttraumatic stress disorder (PTSD): partnering with the FDA. J Psychoactive Drugs34: 185–194
55.
Easton N, Fry J, O'shea E, Watkins A, Kingston S, Marsden C A (2003) Synthesis, in vitro formation, and behavioural effects of glutathione regioisomers of alpha-methyldopamine with relevance to MDA and MDMA (ecstasy). Brain Res987: 144–154
56.
Escobedo I, O'shea E, Orio L, Sanchez V, Segura M, de la Torre R, Farre M, Green A R, Colado M I (2005) A comparative study on the acute and long-term effects of MDMA and 3,4-dihydroxymethamphetamine (HHMA) on brain monoamine levels after i.p. or striatal administration in mice. Br J Pharmacol144: 231–241
57.
Esteban B, O'shea E, Camarero J, Sanchez V, Green A R, Colado M I (2001) 3,4-Methylenedioxymethamphetamine induces monoamine release, but not toxicity, when administered centrally at a concentration occurring following a peripherally injected neurotoxic dose. Psychopharmacology (Berl)154: 251–260
58.
Falk E M, Cook V J, Nichols D E, Sprague J E (2002) An antisense oligonucleotide targeted at MAO-B attenuates rat striatal serotonergic neurotoxicity induced by MDMA. Pharmacol Biochem Behav72: 617–622
59.
Fantegrossi W E, Kiessel C L, De La Garza R 2nd, Woods J H (2005) Serotonin synthesis inhibition reveals distinct mechanisms of action for MDMA and its enantiomers in the mouse. Psychopharmacology (Berl): 181: 529–536
60.
Fantegrossi W E, Godlewski T, Karabenick R L, Stephens J M, Ullrich T, Rice K C, Woods J H (2003) Pharmacological characterization of the effects of 3,4-methylenedioxymethamphetamine (‘ecstasy’) and its enantiomers on lethality, core temperature, and locomotor activity in singly housed and crowded mice. Psychopharmacology (Berl)166: 202–211
61.
Fantegrossi W E, Woolverton W L, Kilbourn M, Sherman P, Yuan J, Hatzidimitriou G, Ricaurte G A, Woods J H, Winger G (2004) Behavioral and neurochemical consequences of long-term intravenous selfadministration of MDMA and its enantiomers by rhesus monkeys. Neuropsychopharmacology29: 1270–1281
62.
Farfel G M, Seiden L S (1995) Role of hypothermia in the mechanism of protection against serotonergic toxicity. I. Experiments using 3,4-methylenedioxymethamphetamine, dizocilpine, CGS 19755 and NBQX. J Pharmacol Exp Ther272: 860–867
63.
Fischer C, Hatzidimitriou G, Wlos J, Katz J, Ricaurte G (1995) Reorganization of ascending 5-HT axon projections in animals previously exposed to the recreational drug (+/-)3,4-methylenedioxymethamphetamine (MDMA, ‘ecstasy’). J Neurosci15: 5476–5485
64.
Fitzgerald J L, Reid J J (1990) Effects of methylenedioxymethamphetamine on the release of monoamines from rat brain slices. Eur J Pharmacol191: 217–220
65.
Fitzgerald J L, Reid J J (1993) Interactions of methylenedioxymethamphetamine with monoamine transmitter release mechanisms in rat brain slices. Naunyn Schmiedebergs Arch Pharmacol347: 313–323
66.
Fitzgerald J L, Reid J J (1994) Sympathomimetic actions of methylenedioxymethamphetamine in rat and rabbit isolated cardiovascular tissues. J Pharm Pharmacol46: 826–832
67.
Fone K C, Beckett S R, Topham I A, Swettenham J, Ball M, Maddocks L (2002)Long-term changes in social interaction and reward following repeated MDMA administration to adolescent rats without accompanying serotonergic neurotoxicity. Psychopharmacology (Berl)159: 437–444
68.
Fox H C, Parrott A C, Turner J J (2001) Ecstasy use: cognitive deficits related to dosage rather than self-reported problematic use of the drug. J Psychopharmacol15: 273–281
69.
Fox H C, McLean A, Turner J J, Parrott A C, Rogers R, Sahakian B J (2002) Neuropsychological evidence of a relatively selective profile of temporal dysfunction in drug-free MDMA (‘ecstasy’) polydrug users. Psychopharmacology (Berl)162: 203–214
70.
Freedman R R, Johanson C E, Tancer M E (2005) Thermoregulatory effects of 3,4-methylenedioxymethamphetamine (MDMA) in humans. Psychopharmacology (Berl)15: 1–9
71.
Gerra G, Zaimovic A, Giucastro G, Maestri D, Monica C, Sartori R, Caccavari R, Delsignore R (1998) Serotonergic function after (+/-)3,4-methylenedioxymethamphetamine (‘Ecstasy’) in humans. Int Clin Psychopharmacol13: 1–9
72.
Gerra G, Zaimovic A, Ferri M, Zambelli U, Timpano M, Neri E, Marzocchi G F, Delsignore R, Brambilla F (2000) Long-lasting effects of (+/-)3,4-methylenedioxymethamphetamine (ecstasy) on serotonin system function in humans. Biol Psychiatry47: 127–136
73.
Gerra G, Zaimovic A, Moi G, Giusti F, Gardini S, Delsignore R, Laviola G, Macchia T, Brambilla F (2002) Effects of (+/-) 3,4-methylenedioxymethamphetamine (ecstasy) on dopamine system function in humans. Behav Brain Res134: 403–410
74.
Gibb J W, Johnson M, Hanson G R (1990) Neurochemical basis of neurotoxicity. Neurotoxicology11: 317–321
75.
Gillman P K (1998) Serotonin syndrome: history and risk. Fundam Clin Pharmacol12: 482–491
76.
Gillman P K (1999) The serotonin syndrome and its treatment. J Psychopharmacol13: 100–109
77.
Gold L H, Hubner C B, Koob G F (1989) A role for the mesolimbic system in the psychostimulant actions of MDMA. Psychopharmacology99: 40–47
78.
Gollamudi R, Ali S F, Lipe G, Newport G, Webb P, Lopez M, Leakey J E, Kolta M, Slikker W Jr (1989) Influence of inducers and inhibitors on the metabolism in vitro and neurochemical effects in vivo of MDMA. Neurotoxicology10: 455–466
79.
Gonzalez F J, Meyer U A (1991) Molecular genetics of the debrisoquine – sparteine polymorphism. Clin Pharmacol Ther50: 233–238
80.
Gordon C J, Watkinson W P, O'Callaghan J P, Miller D B (1991) Effects of 3,4-methylenedioxymethamphetamine on autonomic thermoregulatory responses of the rat. Pharmacol Biochem Behav38: 339–344
81.
Gough B, Ali S F, Slikker W Jr, Holson R R (1991) Acute effects of 3,4-methylenedioxymethamphetamine (MDMA) on monoamines in rat caudate. Pharmacol Biochem Behav39: 619–623
82.
Gouzoulis-Mayfrank E, Thimm B, Rezk M, Hensen G, Daumann J (2003) Memory impairment suggests hippocampal dysfunction in abstinent ecstasy users. Prog Neuropsychopharmacol Biol Psychiatry27: 819–827
83.
Grant R T (1963) Vasodilation and body warming in the rat. J Physiol167: 311–317
84.
Green A R, O'shea E, Colado M I (2004) A review of the mechanisms involved in the acute MDMA (ecstasy)-induced hyperthermic response. Eur J Pharmacol500: 3–13
85.
Green A R, De Souza R J, Williams J L, Murray T K, Cross A J (1992) The neurotoxic effects of methamphetamine on 5-hydroxytryptamine and dopamine in brain: evidence for the protective effect of chlormethiazole. Neuropharmacology. 31: 315–321
86.
Green A R, Mechan A O, Elliott J M, O'shea E, Colado M I (2003) The pharmacology and clinical pharmacology of 3,4-methylenedioxymethamphetamine (MDMA, ‘ecstasy’). Pharmacol Rev55: 463–508
87.
Green A R, O'shea E, Saadat K S, Elliott J M, Colado M I (2005) Studies on the effect of MDMA (‘ecstasy’) on the body temperature of rats housed at different ambient room temperatures. Br J Pharmacol146: 306–312
88.
Gudelsky G A, Nash J F (1996) Carrier-mediated release of serotonin by 3,4-methylenedioxymethamphetamine: implications for serotonindopamine interactions. J Neurochem66: 243–249
89.
Gudelsky G A, Yamamoto B K, Nash J F (1994) Potentiation of 3,4-methylenedioxymethamphetamineinduced dopamine release and serotonin neurotoxicity by 5-HT2 receptor agonists. Eur J Pharmacol264: 325–330
90.
Gurtman C G, Morley K C, Li K M, Hunt G E, McGregor I S (2002) Increased anxiety in rats after 3,4-methylenedioxymethamphetamine: association with serotonin depletion. Eur J Pharmacol446: 89–96
91.
Hatzidimitriou G, McCann U D, Ricaurte G A (1999) Altered serotonin innervation patterns in the forebrain of monkeys treated with (+/-)3,4-methylenedioxymethamphetamine seven years previously: factors influencing abnormal recovery. J Neurosci19: 5096–5107
92.
Henry J A (1992) Ecstasy and the dance of death. BMJ305: 5–6
93.
Hewitt K E, Green A R (1994) Chlormethiazole, dizocilpine and haloperidol prevent the degeneration of serotonergic nerve terminals induced by administration of MDMA (‘Ecstasy’) to rats. Neuropharmacology33: 1589–1595
94.
Heydari A, Yeo K R, Lennard M S, Ellis S W, Tucker G T, Rostami-Hodjegan A (2004) Mechanism-based inactivation of CYP2D6 by methylenedioxymethamphetamine. Drug Metab Dispos32: 1213–1217
95.
Hiramatsu M, Kumagai Y, Unger S E, Cho A K (1990) Metabolism of methylenedioxymethamphetamine: formation of dihydroxymethamphetamine and quinine identified as its glutathione adduct. J Pharmacol Exp Ther254: 521–527
96.
Ho Y J, Pawlak C R, Guo L, Schwarting R K (2004) Acute and long-term consequences of single MDMA administration in relation to individual anxiety levels in the rat. Behav Brain Res149: 135–144
97.
Huether G, Zhou D, Ruther E (1997) Causes and consequences of the loss of serotonergic presynapses elicited by the consumption of 3,4-methylenedioxymethamphetamine (MDMA, ‘ecstasy’) and its congeners. J Neural Transm104: 771–794
98.
Insel T R, Battaglia G, Johannessen J N, Marra S, De Souza E B (1989) 3,4-Methylenedioxymethamphetamine (‘ecstasy’) selectively destroys brain serotonin terminals in rhesus monkeys. J Pharmacol Exp Ther249: 713–720
99.
Irvine R J, Keane M, Felgate P, McCann U D, Callaghan P D, White J M (2005) Plasma drug concentrations and physiological measures in ‘dance party’ participants. Neuropsychopharmacology28: online
100.
Jacobsen L K, Mencl W E, Pugh K R, Skudlarski P, Krystal J H (2004) Preliminary evidence of hippocampal dysfunction in adolescent MDMA (‘ecstasy’) users: possible relationship to neurotoxic effects. Psychopharmacology (Berl)173: 383–390
101.
Johnson E A, O'Callaghan J P, Miller D B (2002) Chronic treatment with supraphysiological levels of corticosterone enhances DMDMAinduced dopaminergic neurotoxicity in the C57BL/6J female mouse. Brain Res933: 130–138
102.
Johnson E A, Sharp D S, Miller D B (2000) Restraint as a stressor in mice: against the dopaminergic neurotoxicity of D-MDMA, low body weight mitigates restraint-induced hypothermia and consequent neuroprotection. Brain Res875: 107–118
103.
Johnson M, Mitros K, Stone D M, Zobrist R, Hanson G R, Gibb J W (1992) Effect of flunarizine and nimodipine on the decrease in tryptophan hydroxylase activity induced by methamphetamine and 3,4-methylenedioxymethamphetamine. J Pharmacol Exp Ther261: 586–591
104.
Johnson M P, Hoffman A J, Nichols D E (1986) Effects of the enantiomers of MDA, MDMA and related analogues on [3H]serotonin and [3H]dopamine release from superfused rat brain slices. Eur J Pharmacol132: 269–276
105.
Jones D C, Duvauchelle C, Ikegami A, Olsen C M, Lau S S, de la Torre R, Monks T J (2005) Serotonergic neurotoxic metabolites of ecstasy identified in rat brain. J Pharmacol Exp Ther313: 422–431
106.
Kehne J H, Ketteler H J, McCloskey T C, Sullivan C K, Dudley M W, Schmidt C J (1996) Effects of the selective 5-HT2A receptor antagonist MDL 100907 on MDMA-induced locomotor stimulation in rats. Neuropsychopharmacology15: 116–124
107.
Kelly P A, Ritchie I M, Quate L, McBean D E, Olverman H J (2002) Functional consequences of perinatal exposure to 3,4-methylenedioxymethamphetamine in rat brain. Br J Pharmacol137: 963–970
108.
Kish S J (2002) How strong is the evidence that brain serotonin neurons are damaged in human users of ecstasy?Pharmacol Biochem Behav71: 845–855
109.
Koch S, Galloway M P (1997) MDMA induced dopamine release in vivo: role of endogenous serotonin. J Neural Transm104: 135–146
110.
Koenig J, Lazarus C, Jeltsch H, Ben Hamida S, Riegert C, Kelche C, Jones B C, Cassel J C (2005) MDMA (ecstasy) effects in pubescent rats: Males are more sensitive than females. Pharmacol Biochem Behav81: 635–644
111.
Kreth K, Kovar K, Schwab M, Zanger U M (2000) Identification of the human cytochromes P450 involved in the oxidative metabolism of ‘Ecstasy’-related designer drugs. Biochem Pharmacol59: 563–1571
112.
Krystal J H, Price L H, Opsahl C, Ricaurte G A, Heninger G R (1992) Chronic 3,4-methylenedioxymethamphetamine (MDMA) use: effects on mood and neuropsychological function?Am J Drug Alcohol Abuse18: 331–341
113.
Kumagai Y, Lin L Y, Hiratsuka A, Narimatsu S, Suzuki T, Yamada H, Oguri K, Yoshimura H, Cho A K (1994) Participation of cytochrome P450-2B and -2D isozymes in the demethylenation of methylenedioxymethamphetamine enantiomers by rats. Mol Pharmacol45: 359–365
114.
Laverty R, Logan B J (1990) Protection by MK 801 and other drugs of methylenedioxymethamphetamine (MDMA) neurotoxicity in rats and mice. Eur J Pharmacol183: 451–452
115.
Lew R, Sabol K E, Chou C, Vosmer G L, Richards J, Seiden L S (1996) Methylenedioxymethamphetamine-induced serotonin deficits are followed by partial recovery over a 52-week period. Part II: Radioligand binding and autoradiography studies. J Pharmacol Exp Ther276: 855–865
116.
Liechti M E, Vollenweider F X (2000) The serotonin uptake inhibitor citalopram reduces acute cardiovascular and vegetative effects of 3,4-mehylenedioxymethamphetamine (‘Ecstasy’) in healthy volunteers. J Psychopharmacol14: 269–274
117.
Lin L Y, Kumagai Y, Cho A K (1992) Enzymatic and chemical demethylenation of (methylenedioxy) amphetamine and (methylenedioxy) methamphetamine by rat brain microsomes. Chem Res Toxicol5: 401–406
118.
Logan B J, Laverty R, Sanderson W D, Yee Y B (1988) Differences between rats and mice in MDMA (methylenedioxymethylamphetamine) neurotoxicity. Eur J Pharmacol152: 227–234
119.
McCann U D, Ricaurte G A (1991) Lasting neuropsychiatric sequelae of (+/-)methylenedioxymethamphetamine (‘ecstasy’) in recreational users. J Clin Psychopharmacol11: 302–305
120.
McCann U D, Ricaurte G A (1992) MDMA (‘ecstasy’) and panic disorder: induction by a single dose. Biol Psychiatry32: 950–953
121.
McCann U D, Slate S O, Ricaurte G A (1996) Adverse reactions with 3,4-methylenedioxymethamphetamine (MDMA; ‘ecstasy’). Drug Saf15: 107–115
122.
McCann U D, Ridenour A, Shaham Y, Ricaurte G A (1994) Serotonin neurotoxicity after (+/-)3,4-methylenedioxymethamphetamine (MDMA; ‘Ecstasy’): a controlled study in humans. Neuropsychopharmacology10: 129–138
123.
McCann U D, Szabo Z, Scheffel U, Dannals R F, Ricaurte G A (1998) Positron emission tomographic evidence of toxic effect of MDMA (‘Ecstasy’) on brain serotonin neurons in human beings. Lancet352: 1433–1437
124.
McCann U D, Eligulashvili V, Mertl M, Murphy D L, Ricaurte G A (1999) Altered neuroendocrine and behavioral responses to mchlorophenylpiperazine in 3,4-methylenedioxymethamphetamine (MDMA) users. Psychopharmacology (Berl)147: 56–65
125.
McCardle K, Luebbers S, Carter J D, Croft R J, Stough C (2004) Chronic MDMA (ecstasy) use, cognition and mood. Psychopharmacology (Berl)173: 434–439
126.
McCreary A C, Bankson M G, Cunningham K A (1999) Pharmacological studies of the acute and chronic effects of (+)-3,4-methylenedioxymethamphetamine on locomotor activity: role of 5-hydroxytryptamine1A and 5-hydroxytryptasmine1B/1D receptors. J Pharmacol Exp Ther290: 965–973
127.
McGregor I S, Clemens K J, Van der Plasse G, Li K M, Hunt G E, Chen F, Lawrence A J (2003) Increased anxiety 3 months after brief exposure to MDMA (‘Ecstasy’) in rats: association with altered 5-HT transporter and receptor density. Neuropsychopharmacology28: 1472–1484
128.
McGuire P (2000) Long-term psychiatric and cognitive effects of MDMA use. Toxicol Lett112–113:153–156
129.
McGuire P, Fahy T (1991) Chronic paranoid psychosis after misuse of MDMA (‘ecstasy’). BMJ302: 697-697
130.
McGuire P K, Cope H, Fahy T A (1994) Diversity of psychopathology associated with use of 3,4-methylenedioxymethamphetamine (‘Ecstasy’). Br J Psychiatry165: 391–395
131.
McKenna D J, Peroutka S J (1990) Neurochemistry and neurotoxicity of 3,4–methylenedioxymethamphetamine (MDMA, ‘ecstasy’). J Neurochem54:14–22
132.
McNamara M G, Kelly J P, Leonard B E (1995) Some behavioural and neurochemical aspects of subacute (+/-)3,4-methylenedioxymethamphetamine administration in rats. Pharmacol Biochem Behav52: 479–484
133.
Malberg J E, Seiden L S (1998) Small changes in ambient temperature cause large changes in 3,4-methylenedioxymethamphetamine (MDMA)-induced serotonin neurotoxicity and core body temperature in the rat. J Neurosci18: 5086–5094
134.
Malberg J E, Sabol K E, Seiden L S (1996) Co-administration of MDMA with drugs that protect against MDMA neurotoxicity produces different effects on body temperature in the rat. J Pharmacol Exp Ther278: 258–267
135.
Malpass A, White J M, Irvine R J, Somogyi A A, Bochner F (1999) Acute toxicity of 3,4-methylenedioxymethamphetamine (MDMA) in Sprague-Dawley and Dark Agouti rats. Pharmacol Biochem Behav64: 29–34
136.
Mann H, Ladenheim B, Hirata H, Moran T H, Cadet J L (1997) Differential toxic effects of methamphetamine (METH) and methylenedioxymethamphetamine (MDMA) in multidrug-resistant (mdr1a) knockout mice. Brain Res769: 340–346
137.
Marston H M, Reid M E, Lawrence J A, Olverman H J, Butcher S P (1999) Behavioural analysis of the acute and chronic effects of MDMA treatment in the rat. Psychopharmacology (Berl)144: 67–76
138.
Mechan A O, O'shea E, Elliot J M, Colado M I, Green A R (2001) A neurotoxic dose of 3, 4-methylenedioxymethamphetamine (MDMA; ecstasy) to rats results in a long-term defect in thermoregulation. Psychopharmacology155: 413–418
139.
Mechan A O, Esteban B, O'shea E, Elliot J M, Colado M I, Green A R (2002) The pharmacology of the acute hyperthermic response that follows administration of 3,4-methylenedioxymethamphetamine (MDMA ‘ecstasy’) to rats. Br J Pharmacol135: 170–180
140.
Miller D B, O'Callaghan J P (1994) Environment-, drug- and stressinduced alterations in body temperature affects the neurotoxicity of substituted amphetamines in the C57BL/6J mouse. J Pharmacol Exp Ther270: 752–760
141.
Miller D B, O'Callaghan J P (1995) The role of temperature, stress, and other factors in the neurotoxicity of the substituted amphetamines 3,4-methylenedioxymethamphetamine and fenfluramine. Mol Neurobiol11: 177–192
142.
Miller R T, Lau S S, Monks T J (1996) Effects of intracerebroventricular administration of 5-(glutathion-S-yl)-alpha-methyldopamine on brain dopamine, serotonin, and norepinephrine concentrations in male Sprague-Dawley rats. Chem Res Toxicol9: 457–465
143.
Miller R T, Lau S S, Monks T J (1997) 2,5-Bis-(glutathion-S-yl)alphamethyldopamine, a putative metabolite of (+/-)-3,4-methylenedioxyamphetamine, decreases brain serotonin concentrations. Eur J Pharmacol323: 173–180
144.
Moeller F G, Steinberg J L, Dougherty D M, Narayana P A, Kramer L A, Renshaw P F (2004) Functional MRI study of working memory in MDMA users. Psychopharmacology (Berl)177: 185–194
145.
Molliver M E, Mamounas L A, Wilson M A (1989) Effects of neurotoxic amphetamines on serotonergic neurons: immunocytochemical studies. NIDA Res Monogr94: 270–305
146.
Molliver M E, O'Hearn E, Battaglia G, De Souza ER (1986) Direct intracerebral administration of MDMA and MDA does not produce serotonin neurotoxicity. Soc Neurosci Abstr12: 1234-1234
147.
Monson C B, Oyama J (1984) Core temperature of tailless rats exposed to centrifugation. Physiologist27: S97–S98
148.
Mordenti J, Chappell W (1989) The use of interspecies scaling in toxicokinetics. In Yacogi A, Kelly J, Batra V (eds), Toxicokinetics and New Drug Development. Pergamon Press, New York, pp. 42–96
149.
Morgan M J (1999) Memory deficits associated with recreational use of ‘ecstasy’ (MDMA). Psychopharmacology (Berl)141: 30–36
150.
Morgan M J (2000) Ecstasy (MDMA): a review of its possible persistent psychological effects. Psychopharmacology (Berl)152: 230–248
151.
Morley K C, Arnold J C, McGregor I S (2005) Serotonin (1A) receptor involvement in acute 3,4-methylenedioxymethamphetamine (MDMA) facilitation of social interaction in the rat. Prog Neuropsychopharmacol. Biol Psychiatry29: 648–657
152.
Morley K C, Gallate J E, Hunt G E, Mallet P E, McGregor I S (2001) Increased anxiety and impaired memory in rats 3 months after administration of 3,4-methylenedioxymethamphetamine (‘ecstasy’). Eur J Pharmacol433: 91–99
Nash J F, Yamamoto B K (1992) Methamphetamine neurotoxicity and striatal glutamate release: comparison to 3,4-methylenedioxymethamphetamine. Brain Res581: 237–243
155.
Nash J F Jr, Meltzer H Y, Gudelsky G A (1988) Elevation of serum prolactin and corticosterone concentrations in the rat after the administration of 3,4-methylenedioxymethamphetamine. J Pharmacol Exp Ther245: 873–879
156.
Nixdorf W L, Burrows K B, Gudelsky G A, Yamamoto B K (2001) Enhancement of 3,4-methylenedioxymethamphetamine neurotoxicity by the energy inhibitor malonate. J Neurochem77: 647–654
157.
Obradovic T, Imel K M, White S R (1998) Repeated exposure to methylenedioxymethamphetamine (MDMA) alters nucleus accumbens neuronal responses to dopamine and serotonin. Brain Res785: 1–9
158.
Obrocki J, Buchert R, Vaterlein O, Thomasius R, Beyer W, Schiemann T (1999) Ecstasy – long-term effects on the human central nervous system revealed by positron emission tomography. Br J Psychiatry175: 186–188
159.
O'Cain P A, Hletko S B, Ogden B A, Varner K J (2000) Cardiovascular and sympathetic responses and reflex changes elicited by MDMA. Physiol Behav70: 141–148
160.
O'Callaghan J P, Miller D B (1994) Neurotoxicity profiles of substituted amphetamines in the C57BL/6J mouse. J Pharmacol Exp Ther270: 741–751
161.
O'shea E, Granados R, Esteban B, Colado M I, Green A R (1998) The relationship between the degree of neurodegeneration of rat brain 5-HT nerve terminals and the dose and frequency of administration of MDMA (‘ecstasy’). Neuropharmacology37: 919–926
162.
O'shea E, Esteban B, Camarero J, Green A R, Colado M I (2001) Effect of GBR 12909 and fluoxetine on the acute and long-term changes induced by MDMA (‘ecstasy’) on the 5-HT and dopamine concentrations in mouse brain. Neuropharmacology40: 65–74
163.
Paris J M, Cunningham K A (1992) Lack of serotonin neurotoxicity after intraraphe microinjection of (+)-3,4-methylenedioxymethamphetamine (MDMA). Brain Res Bull28: 115–119
164.
Parrott A C (2001) Human psychopharmacology of Ecstasy (MDMA): a review of 15 years of empirical research. Hum Psychopharmacol16: 557–577
165.
Parrott A C (2002) Recreational Ecstasy/MDMA, the serotonin syndrome, and serotonergic neurotoxicity. Pharmacol Biochem Behav71: 837–844
166.
Parrott A C, Lasky J (1998) Ecstasy (MDMA) effects upon mood and cognition: before, during and after a Saturday night dance. Psychopharmacology (Berl)139: 261–268
167.
Parrott A C, Sisk E, Turner J J (2000) Psychobiological problems in heavy ‘ecstasy’ (MDMA) polydrug users. Drug Alcohol Depend60: 105–110
168.
Parrott A C, Lees A, Garnham N J, Jones M, Wesnes K (1998) Cognitive performance in recreational users of MDMA of ‘ecstasy’: evidence for memory deficits. J Psychopharmacol12: 79–83
169.
Pedersen N P, Blessing W W (2001) Cutaneous vasoconstriction contributes to hyperthermia induced by 3,4-methylenedioxymethamphetamine (ecstasy) in conscious rabbits. J Neurosci21: 8648–8654
170.
Piper B J, Meyer J S (2004) Memory deficit and reduced anxiety in young adult rats given repeated intermittent MDMA treatment during the periadolescent period. Pharmacol Biochem Behav79: 723–731
171.
Piper B J, Fraiman J B, Meyer J S (2005) Repeated MDMA (‘Ecstasy’) exposure in adolescent male rats alters temperature regulation, spontaneous motor activity, attention, and serotonin transporter binding. Dev Psychobiol47: 145–157
172.
Pizarro N, Farre M, Pujadas M, Peiro A M, Roset P N, Joglar J, de la Torre R (2004) Stereochemical analysis of 3,4-methylenedioxymethamphetamine and its main metabolites in human samples including the catechol-type metabolite (3,4-dihydroxymethamphetamine). Drug Metab Dispos32: 1001–1007
173.
Price L H, Ricaurte G A, Krystal J H, Heninger G R (1989) Neuroendocrine and mood responses to intravenous L-tryptophan in 3,4-methylenedioxymethamphetamine (MDMA) users. Preliminary observations. Arch Gen Psychiatry46: 20–22
174.
Reneman L, Booij J, Habraken J B, De Bruin K, Hatzidimitriou G, Den Heeten G J, Ricaurte G A (2002) Validity of [123I]beta-CIT SPECT in detecting MDMA-induced serotonergic neurotoxicity. Synapse46: 199–205
175.
Reneman L, Booij J, de Bruin K, Reitsma J B, de Wolff F A, Gunning W B, den Heeten G J, van den Brink W (2001) Effects of dose, sex, and long-term abstention from use on toxic effects of MDMA (ecstasy) on brain serotonin neurons. Lancet358: 1864–1869
176.
Reveron M E, Monks T J, Duvauchelle C L (2005) Age-dependent (+)MDMA-mediated Neurotoxicity in Mice. Neurotoxicology2: online
177.
Ricaurte G A, McCann U D (1992) Neurotoxic amphetamine analogues: effects in monkeys and implications for humans. Ann N Y Acad Sci648: 371–382
178.
Ricaurte G A, DeLanney L E, Irwin I, Langston J W (1988a) Toxic effects of MDMA on central serotonergic neurons in the primate: importance of route and frequency of drug administration. Brain Res446: 165–168
179.
Ricaurte G A, McCann U D, Szabo Z, Scheffel U (2000) Toxicodynamics and long-term toxicity of the recreational drug, 3, 4-methylenedioxymethamphetamine (MDMA, ‘Ecstasy’). Toxicol Lett112–113: 143–146
180.
Ricaurte G A, DeLanney L E, Wiener S G, Irwin I, Langston J W (1988b) 5-Hydroxyindoleacetic acid in cerebrospinal fluid reflects serotonergic damage induced by 3,4-methylenedioxymethamphetamine in CNS of non-human primates. Brain Res474: 359–363
181.
Ricaurte G A, Forno L S, Wilson M A, DeLanney L E, Irwin I, Molliver M E, Langston J W (1988c) (+/-)3,4-Methylenedioxymethamphetamine selectively damages central serotonergic neurons in nonhuman primates. Jama260: 51–55
182.
Romanovsky A A, Ivanov A I, Shimansky Y P (2002) Selected contribution: ambient temperature for experiments in rats: a new method for determining the zone of thermal neutrality. J Appl Physiol92: 2667–2679
183.
Saadat K S, Elliott J M, Colado M I, Green A R (2004) Hyperthermic and neurotoxic effect of 3,4-methylenedioxymethamphetamine (MDMA) in guinea pigs. Psychopharmacology (Berl)173: 452–453
184.
Saadat K S, O'shea E, Colado M I, Elliott J M, Green A R (2005) The role of 5-HT in the impairment of thermoregulation observed in rats administered MDMA (‘ecstasy’) when housed at high ambient temperature. Psychopharmacology (Berl)179: 884–890
185.
Sabol K E, Seiden L S (1998) Reserpine attenuates D-amphetamine and MDMA-induced transmitter release in vivo: a consideration of dose, core temperature and dopamine synthesis. Brain Res806: 69–78
186.
Sabol K E, Lew R, Richards J B, Vosmer G L, Seiden L S (1996) Methylenedioxymethamphetamineinduced serotonin deficits are followed by partial recovery over a 52-week period. Part I: Synaptosomal uptake and tissue concentrations. J Pharmacol Exp Ther276: 846–854
187.
Sanchez V, Camarero J, O'shea E, Green A R, Colado M I (2003) Differential effect of dietary selenium on the long-term neurotoxicity induced by MDMA in mice and rats. Neuropharmacology44: 449–461
188.
Sanchez V, O'shea E, Saadat K S, Elliott J M, Colado M I, Green A R (2004) Effect of repeated (‘binge’) dosing of MDMA to rats housed at normal and high temperature on neurotoxic damage to cerebral 5-HT and dopamine neurones. J Psychopharmacol18: 412–416
189.
Scheffel U, Szabo Z, Mathews W B, Finley P A, Dannals R F, Ravert H T, Szabo K, Yuan J, Ricaurte G A (1998) In vivo detection of short- and long-term MDMA neurotoxicity – a positron emission tomography study in the living baboon brain. Synapse29: 183–192
190.
Schifano F (1991) Chronic atypical psychosis associated with MDMA (‘ecstasy’) abuse. Lancet338: 1335-1335
191.
Schifano F (2004) A bitter pill. Overview of ecstasy (MDMA, MDA) related fatalities. Psychopharmacology (Berl)173: 242–248
192.
Schmidt C J (1987) Neurotoxicity of the psychedelic amphetamine, methylenedioxymethamphetamine. J Pharmacol Exp Ther240: 1–7
193.
Schmidt C J, Kehne J H (1990) Neurotoxicity of MDMA: neurochemical effects. Ann N Y Acad Sci600: 665–680; 680–681
194.
Schmidt C J, Taylor V L (1988) Direct central effects of acute methylenedioxymethamphetamine on serotonergic neurons. Eur J Pharmacol156: 121–131
195.
Schmidt C J, Black C K, Taylor V L (1990a) Antagonism of the neurotoxicity due to a single administration of methylenedioxymethamphetamine. Eur J Pharmacol181: 59–70
196.
Schmidt C J, Abbate G M, Black C K, Taylor V L (1990b) Selective 5-hydroxytryptamine2 receptor antagonists protect against the neurotoxicity of methylenedioxymethamphetamine in rats. J Pharmacol Exp Ther255: 478–483
197.
Schmidt C J, Black C K, Abbate G M, Taylor V L (1990c) Methylenedioxymethamphetamineinduced hyperthermia and neurotoxicity are independently mediated by 5-HT2 receptors. Brain Res529: 85–90
198.
Schmidt C J, Taylor V L, Abbate G M, Nieduzak T R (1991) 5-HT2 antagonists stereoselectively prevent the neurotoxicity of 3,4-methylenedioxymethamphetamine by blocking the acute stimulation of dopamine synthesis: reversal by L-dopa. J Pharmacol Exp Ther256: 230–235
199.
Segura M, Farre M, Pichine S, Peiro A M, Roset P N, Ramirez A, Ortuno J, Pacifici R, Zuccaro P, Segura J, de la Torre R (2005) Contribution of cytochrome P450 2D6 to 3,4-methylenedioxymethamphetamine disposition in humans: use of paroxetine as a metabolic inhibitor probe. Clin Pharmacokinet44: 649–660
200.
Segura M, Ortuno J, Farre M, McLure J A, Pujadas M, Pizarro N, Llebaria A, Joglar J, Roset P N, Segura J, de La Torre R (2001) 3,4-Dihydroxymethamphetamine (HHMA). A major in vivo 3,4-methylenedioxymethamphetamine (MDMA) metabolite in humans. Chem Res Toxicol14: 1203–1208
201.
Semple D M, Ebmeier K P, Glabus M F, O'Carroll R E, Johnstone E C (1999) Reduced in vivo binding to the serotonin transporter in the cerebral cortex of MDMA (‘ecstasy’) users. Br J Psychiatry175: 63–69
202.
Shankaran M, Gudelsky G A (1999) A neurotoxic regimen of MDMA suppresses behavioral, thermal and neurochemical responses to subsequent MDMA administration. Psychopharmacology (Berl)147: 66–72
203.
Shankaran M, Yamamoto B K, Gudelsky G A (1999) Mazindol attenuates the 3,4-methylenedioxymethamphetamine-induced formation of hydroxyl radicals and long-term depletion of serotonin in the striatum. J Neurochem72: 2516–2522
204.
Slikker W Jr, Bowyer J F (2005) Biomarkers of adult and developmental neurotoxicity. Toxicol Appl Pharmacol206: 255–260
205.
Slikker W Jr, Ali S F, Scallet A C, Frith C H, Newport G D, Bailey J R (1988) Neurochemical and neurohistological alterations in the rat and monkey produced by orally administered methylenedioxymethamphetamine (MDMA). Toxicol Appl Pharmacol94: 448–457
206.
Slikker W Jr, Holson R R, Ali S F, Kolta M G, Paule M G, Scallet A C, McMillan D E, Bailey J R, Hong J S, Scalzo F M (1989) Behavioral and neurochemical effects of orally administered MDMA in the rodent and nonhuman primate. Neurotoxicology10: 529–542
207.
Spanos L J, Yamamoto B K (1989) Acute and subchronic effects of methylenedioxymethamphetamine [(+/-)MDMA] on locomotion and serotonin syndrome behavior in the rat. Pharmacol Biochem Behav32: 835–840
208.
Spear L P (2000) The adolescent brain and age-related behavioural manifestations. Neurosci Biobehav Rev24: 417–463
209.
Sprague J E, Nichols D E (2005) Neurotoxicity of MDMA (ecstasy): beyond metabolism. Trends Pharmacol Sci26: 59–60; 60–61
210.
Sprague J E, Everman S L, Nichols D E (1998) An integrated hypothesis for the serotonergic axonal loss induced by 3,4-methylenedioxymethamphetamine. Neurotoxicology19: 427–441
211.
St Omer V E, Ali S F, Holson R R, Duhart H M, Scalzo F M, Slikker W Jr (1991) Behavioral and neurochemical effects of prenatal methylenedioxymethamphetamine (MDMA) exposure in rats. Neurotoxicol Teratol13: 13–20
212.
Stone D M, Hanson G R, Gibb J W (1987a) Differences in the central serotonergic effects of methylenedioxymethamphetamine (MDMA) in mice and rats. Neuropharmacology26: 1657–1661
213.
Stone D M, Johnson M, Hanson G R, Gibb J W (1988) Role of endogenous dopamine in the central serotonergic deficits induced by 3,4-methylenedioxymethamphetamine. J Pharmacol Exp Ther247: 79–87
214.
Stone D M, Merchant K M, Hanson G R, Gibb J W (1987b) Immediate and long-term effects of 3,4-methylenedioxymethamphetamine on serotonin pathways in brain of rat. Neuropharmacology26: 1677–1683
215.
Stone D M, Stahl D C, Hanson G R, Gibb J W (1986) The effects of 3,4-methylenedioxymethamphetamine (MDMA) and 3,4-methylenedioxyamphetamine (MDA) on monoaminergic systems in the rat brain. Eur J Pharmacol128: 41–48
216.
Sugimoto Y, Okhura M, Inoue K, Yamada J (2001) Involvement of serotonergic and dopaminergic mechanisms in hyperthermia induced by a serotonin-releasing drug, p-chloroamphetamine in mice. Eur J Pharmacol430: 265–268
217.
Szabo Z, Scheffel U, Suehiro M, Dannals R F, Kim S E, Ravert H T, Ricaurte G A, Wagner H N Jr (1995) Positron emission tomography of 5-HT transporter sites in the baboon brain with [11C]McN5652. J Cereb Blood Flow Metab15: 798–805
218.
Szabo Z, McCann U D, Wilson A A, Scheffel U, Owonikoko T, Mathews W B, Ravert H T, Hilton J, Dannals R F, Ricaurte G A (2002) Comparison of (+)-(11)C-McN5652 and (11)C-DASB as serotonin transporter radioligands under various experimental conditions. J Nucl Med43: 678–692
219.
Tucker G T, Lennard M S, Ellis S W, Woods H F, Cho A K, Lin L Y, Hiratsuka A, Schmitz D A, Chu T Y (1994) The demethylenation of methylenedioxymethamphetamine (‘ecstasy’) by debrisoquine hydroxylase (CYP2D6)Biochem Pharmacol47: 1151–1156
220.
Veryheyden S L, Hadfield J, Calin T, Curran H V (2002). Sub-acute effects of MDMA (± 3,4-methylenedioxymethamphetamine ‘ecstasy’) on mood: evidence of gender differences. Psychopharmacology161: 23–31
221.
Vollenweider F X, Jones R T, Baggott M J (2001) Caveat emptor: editors beware. Neuropsychopharmacology24: 461–463
222.
Vollenweider F X, Gamma A, Liechti M, Huber T (1998) Psychological and cardiovascular effects and short-term sequelae of MDMA (‘ecstasy’) in MDMA-naive healthy volunteers. Neuropsychopharmacology19: 241–251
223.
Vorhees C V, Reed T M, Skelton M R, Williams M T (2004) Exposure to 3,4-methylenedioxymethamphetamine (MDMA) on postnatal days 11–20 induces reference but not working memory deficits in the Morris water maze in rats: implications of prior learning. Int J Dev Neurosci22: 247–259
224.
Wallace T L, Gudelsky G A, Vorhees C V (2001) Alterations in diurnal and nocturnal locomotor activity in rats treated with a monoaminedepleting regimen of methamphetamine or 3,4-methylenedioxymethamphetamine. Psychopharmacology (Berl)153: 321–326
225.
Wareing M, Fisk J E, Murphy P N (2000) Working memory deficits in current and previous users of MDMA (‘ecstasy’). Br J Psychol91 (Pt 2): 181–188
226.
Wareing M, Murphy P N, Fisk J E (2004a) Visuospatial memory impairments in users of MDMA (‘ecstasy’). Psychopharmacology (Berl)173: 391–397
227.
Wareing M, Fisk J E, Murphy P, Montgomery C (2004b) Verbal working memory deficits in current and previous users of MDMA. Hum Psychopharmacol19: 225–234
228.
Wareing M, Fisk J E, Murphy P, Montgomery C (2005) Visuo-spatial working memory deficits in current and former users of MDMA (‘ecstasy’). Hum Psychopharmacol20: 115–123
229.
Wilson M A, Ricaurte G A, Molliver M E (1989) Distinct morphologic classes of serotonergic axons in primates exhibit differential vulnerability to the psychotropic drug 3,4-methylenedioxymethamphetamine. Neuroscience28: 121–137
230.
Winstock A R, Wolff K, Ramsey J (2001) Ecstasy pill testing: harm minimization gone too far?Addiction96: 1139–1148
231.
Wu Y, Jiji L M, Lemons D E, Weinbaum S (1995) A non-uniform threedimensional perfusion model of rat tail heat transfer. Phys Med Biol40: 789–806
232.
Xie T, McCann U D, Kim S, Yuan J, Ricaurte G A (2000) Effect of temperature on dopamine transporter function and intracellular accumulation of methamphetamine: implications for methamphetamine-induced dopaminergic neurotoxicity. Journal of Neuroscience20: 7838–7845
233.
Yamamoto B K, Spanos L J (1988) The acute effects of methylenedioxymethamphetamine on dopamine release in the awake-behaving rat. Eur J Pharmacol148: 195–203
234.
Yamamoto B K, Nash J F, Gudelsky G A (1995) Modulation of methylenedioxymethamphetamineinduced striatal dopamine release by the interaction between serotonin and gamma-aminobutyric acid in the substantia nigra. J Pharmacol Exp Ther273: 1063–1070
235.
Yeh S Y, Hsu F L (1991) The neurochemical and stimulatory effects of putative metabolites of 3,4-methylenedioxymethamphetamine in rats. Pharmacol Biochem Behav39: 787–790
236.
Yuan J, Cord B J, McCann U D, Callahan B T, Ricaurte G A (2002) Effect of depleting vesicular and cytoplasmic dopamine on methylenedioxymethamphetamine neurotoxicity. J Neurochem80: 960–969
